Printer Friendly

Australia Gains Dry Eye Disease Treatment with Novaliq's NovaTears.

M2 PHARMA-July 3, 2018-Australia Gains Dry Eye Disease Treatment with Novaliq's NovaTears

(C)2018 M2 COMMUNICATIONS

- Heidelberg, Germany-based ophthalmic pharmaceutical company Novaliq has made NovaTears, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), available in Australia, the company said.

Eight months after launching in New Zealand, AFT Pharmaceuticals Ltd has achieved registration of NovaTears in Australia. AFT, a New Zealand-based pharmaceutical company is commercializing NovaTears across Australasia.

Clinically validated in four clinical trials, the water-free topical eye drop treatment NovaTears has been proven to be safe and efficacious for treating the signs and symptoms of DED and MGD.

A large number of objective disease parameters such as tear film breakup time, corneal and conjunctival fluorescein staining, the number of expressible meibomian glands, and meibum quality have been improved under NovaTears treatment.

The mission of Novaliq is to transform ocular therapeutics based on EyeSol, a water-free technology that enhances the topical bio-availability, stability, and safety of traditionally insoluble or unstable drugs.

Novaliq has developed a tiered portfolio of differentiated products addressing the needs of eye patients.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:8AUST
Date:Jul 3, 2018
Words:192
Previous Article:Helix Closes USD 200m Series B Financing to Further Expand into Consumer Genomics.
Next Article:Freenome and the Medical University of Graz Receive Christian Doppler Research Grant.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |